Former Pfizer employee convicted of insider trading on COVID drug Paxlovid trial
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-01-22 04:41 GMT | Update On 2024-03-26 10:00 GMT
Advertisement
A former employee of Pfizer Inc was convicted of insider trading on Thursday for buying stock options in November 2021 just before Pfizer announced clinical trial results for the COVID antiviral drug Paxlovid, federal prosecutors said.
A federal jury in Manhattan found Amit Dagar, 44, of Hillsborough, New Jersey, guilty on one count of securities fraud, prosecutors said. Prosecutors alleged Dagar had traded and tipped a friend on Nov. 4, 2021, the day before the drug maker announced that Paxlovid had performed well in the trial.
U.S. Attorney Damian Williams said the verdict is a warning to "would-be insider traders tempted by the prospect of easy money."
An attorney for Dagar did not immediately reply to a request for comment.
Dagar was a senior statistical program lead for the Paxlovid drug trial, according to the U.S. Securities and Exchange Commission's parallel civil case against Dagar and his friend Atul Bhiwapurkar.
Bhiwapurkar pleaded guilty to securities fraud in October.
The charges carry maximum sentences of 20 years, but any sentences would likely be much lower and would be imposed by the judge based on several factors.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.